Author:
Koeberl D. D.,Kishnani P. S.,Chen Y. T.
Subject
Genetics(clinical),Genetics
Reference45 articles.
1. Amalfitano A, McVie-Wylie AJ, Hu H, et al (1999) Systemic correction of the muscle disorder glycogen storage disease type II after hepatic targeting of a modified adenovirus vector encoding human acid-alpha-glucosidase. Proc Natl Acad Sci USA 96: 8861–8866.
2. Amalfitano A, Bengur AR, Morse RP, et al (2001) Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial. Genet Med 3: 132–138.
3. An Y, Young SP, Kishnani PS, et al (2005) Glucose tetrasaccharide as a biomarker for monitoring the therapeutic response to enzyme replacement therapy for Pompe disease. Mol Genet Metab 85: 247–254.
4. Beaty RM, Jackson M, Peterson D, et al (2002) Delivery of glucose-6-phosphatase in a canine model for glycogen storage disease, type Ia, with adeno-associated virus (AAV) vectors. Gene Ther 9: 1015–1022.
5. Bijvoet AG, Van Hirtum H, Kroos MA, et al (1999) Human acid alphaglucosidase from rabbit milk has therapeutic effect in mice with glycogen storage disease type II. Hum Mol Genet 8: 2145–2153.
Cited by
61 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献